Lisata Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Lisata Therapeutics is Dave Mazzo, benoemd in Jan2015, heeft een ambtstermijn van 9.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.41M, bestaande uit 48% salaris en 52% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.26% van de aandelen van het bedrijf, ter waarde $ 301.39K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.1 jaar en 9 jaar.

Belangrijke informatie

Dave Mazzo

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris	48.0%
Dienstverband CEO	9.8yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	4.1yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Dave Mazzo's beloning veranderd ten opzichte van Lisata Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$21m
Jun 30 2024	n/a	n/a	-US$21m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$1m	US$676k	-US$21m
Sep 30 2023	n/a	n/a	-US$21m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	US$2m	US$650k	-US$54m
Sep 30 2022	n/a	n/a	-US$55m
Jun 30 2022	n/a	n/a	-US$25m
Mar 31 2022	n/a	n/a	-US$24m
Dec 31 2021	US$1m	US$631k	-US$27m
Sep 30 2021	n/a	n/a	-US$26m
Jun 30 2021	n/a	n/a	-US$25m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$1m	US$613k	-US$8m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	n/a	n/a	-US$7m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$2m	US$597k	-US$19m
Sep 30 2019	n/a	n/a	-US$18m
Jun 30 2019	n/a	n/a	-US$17m
Mar 31 2019	n/a	n/a	-US$16m
Dec 31 2018	US$2m	US$594k	-US$16m
Sep 30 2018	n/a	n/a	-US$17m
Jun 30 2018	n/a	n/a	-US$17m
Mar 31 2018	n/a	n/a	-US$14m
Dec 31 2017	US$1m	US$577k	-US$16m

Compensatie versus markt: De totale vergoeding ($USD 1.41M ) Dave } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 354.22K ).

Compensatie versus inkomsten: De vergoeding van Dave is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Dave Mazzo (67 yo)

9.8yrs

Tenure

US$1,408,382

Compensatie

Dr. David J. Mazzo, also known as Dave, B.A. (Hons), B.Sc. (Hons.), M.Sc., Ph D., served as Independent Non Executive Chairman at Visioneering Technologies, Inc. since February 28, 2020 until February 29,...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
David Mazzo	President	9.8yrs	US$1.41m	1.26% $ 301.4k
Kristen Buck	Executive VP of R&D and Chief Medical Officer	3.2yrs	US$969.82k	0.75% $ 180.5k
James Nisco	Senior VP of Finance	3.7yrs	geen gegevens	0.042% $ 10.0k
Tariq Imam	Vice President of Business Development & Operations and Corporate Counsel	1.8yrs	geen gegevens	geen gegevens
Gregory Berkin	Chief Information & Data Protection Officer	4.1yrs	geen gegevens	geen gegevens
John Menditto	Vice President of Investor Relations & Corporate Communications	6.9yrs	geen gegevens	geen gegevens
Gail Holler	Vice President of Human Resources	5.8yrs	geen gegevens	geen gegevens
William Sietsema	Vice President of Global Regulatory Affairs	no data	US$400.18k	geen gegevens

4.1yrs

Gemiddelde duur

65yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 0HS8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
David Mazzo	President	9.8yrs	US$1.41m	1.26% $ 301.4k
Steven Klosk	Independent Director	10.3yrs	US$120.00k	0.0052% $ 1.2k
Gregory Brown	Independent Chairman of the Board	8.1yrs	US$149.50k	0.0033% $ 795.5
Heidi Henson	Independent Director	2.2yrs	US$124.00k	0% $ 0
Gerald Nepom	Member of Type 1 Diabetes Scientific Advisory Board	no data	geen gegevens	geen gegevens
Robert Negrin	Immune Modulation Program Advisor	no data	geen gegevens	geen gegevens
Robert Korngold	Immune Modulation Program Advisor	no data	geen gegevens	geen gegevens
David Pearce	Member of Type 1 Diabetes Scientific Advisory Board	no data	geen gegevens	geen gegevens
David Horwitz	Immune Modulation Program Advisor	no data	geen gegevens	geen gegevens
David Peritt	Immune Modulation Program Advisor	no data	geen gegevens	geen gegevens
Noel Warner	Immune Modulation Program Advisor	no data	geen gegevens	geen gegevens
Kevan Herold	Member of Type 1 Diabetes Scientific Advisory Board	no data	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 0HS8 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Lisata Therapeutics Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Lisata Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Second-Line Cholangiocarcinoma Cohort of the BOLSTER Trial

Lisata Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Lisata Therapeutics, Inc. Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Lisata Therapeutics, Inc. Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in A Preclinical Model

Lisata Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Lisata Therapeutics, Inc., Annual General Meeting, Jun 27, 2024

Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

Lisata Therapeutics, Inc. to Report Fiscal Year 2023 Results on Feb 29, 2024

Lisata Therapeutics, Inc. Announces First Patient Treated in the Phase 2A Trial of Lsta1 in Patients with Glioblastoma Multiforme

Lisata Therapeutics, Inc. Announces Completion of Enrollment in Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. Announces LSTA1 as A Treatment for Solid Tumor Cancers in Combination with Other Anti-Cancer Agents

New major risk - Revenue and earnings growth

Lisata Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Lisata Therapeutics, Inc. Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1

Lisata Therapeutics, Inc. Announces Outcome of Interim Futility Analysis for Its Phase 2B Ascend Trial of Lsta1 in Metastatic Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Lisata Therapeutics, Inc. Announces Retirement of Erkki Ruoslahti from Board of Directors

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2B Ascend Trial of LSTA1

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) completed the acquisition of Cend Therapeutics Inc.

Insufficient new directors

Nasdaq Grants Caladrius Biosciences an Extension Through February 13, 2023 to Evidence Compliance with the Bid Price Requirement

Caladrius Biosciences, Inc Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Insufficient new directors

Caladrius Biosciences and Cend Therapeutics Announce Publication of Pancreatic Cancer Trial Data in the Lancet Gastroenterology and Hepatology

Insufficient new directors

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA(R) in Coronary Microvascular Dysfunction

Caladrius Biosciences Inc. Announces IDMC Recommendation to Advance Clbs201 Trial for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. (NasdaqCM:CLBS) entered into a definitive merger agreement to acquire Cend Therapeutics Inc. for $38.1 million.

Insufficient new directors

Caladrius Biosciences, Inc. Treats First Patient in the Phase 1B Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

Todd C. Girolamo Intent to Resign as Chief Legal Officer, Senior Vice President of Corporate Development and Corporate Secretary of Caladrius Biosciences, Inc., Effective March 14, 2022

Forecast to breakeven in 2025

Caladrius Biosciences to Assess Its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease

Caladrius Biosciences, Inc. Announces Orphan Drug Designation for CLBS12 for the Treatment of Buerger’s Disease

Caladrius Biosciences, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Caladrius Biosciences, Inc. announced that it has received $25 million in funding

Caladrius Biosciences, Inc. announced that it expects to receive $25 million in funding

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd